MedComm | A dual MET/AXL small‐molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment

2020-06-16

Open the phone and scan

There are two kinds of receptor tyrosine kinases --MET and AXL --which are intimately bound up with tumorigenesis and aggressiveness of multiple malignancies. However, the molecular mechanism of MET and AXL in both processes is yet not quite clear. In the present study, Chenjing Zhu et al evaluated the antitumor impact of LY2801653, a dual MET and AXL inhibitor on gastric cancer and to elucidate the underlying mechanisms.


Fig. 1 MET and AXL expression in human gastric cancer cell lines and gastric cancer patients’ tumors.

 

 

 

Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.11

 

 

                                                                           

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.

 


Last page：MedComm | Vitamin intervention for cytokine storm in the patients with coronavirus disease 2019 Next page：MedComm | Intermedin promotes vessel fusion by inducing VE‐cadherin accumulation at potential fusion sites and to achieve a dynamic balance between VE‐cadherin‐complex dissociation/reconstitution